In the APT trial, the 3-year rate of recurrence-free survival (RFS) was 99.2% (95% CI 98.4–100), and there was no difference in subgroups defined according to tumor size (≤ 1 cm vs. > 1 cm) or hormone receptor status (positive vs. negative) [27]. This evidence concerns the gene NR4A1 and neoplasm.